CFM
MAZE

Cornerstone Financial Management’s Maze Therapeutics MAZE Stock Holding History

Cornerstone Financial Management’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$836 Hold
28
– – ﹤0.01% 1167
2026
Q1 		$836 Hold
28
– – ﹤0.01% 1033
2025
Q4 		$1.16K Buy
+28
New +$962 ﹤0.01% 873

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Cornerstone Financial Management's MAZE Position: Q2 2026 in Review

Cornerstone Financial Management held its Maze Therapeutics (MAZE) position steady in Q2 2026 at 28 shares worth $836. The position accounts for ﹤0.01% of the portfolio, ranked #1167.

Cornerstone Financial Management first reported a position in MAZE in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.16K in Q4 2025. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Cornerstone Financial Management held 28 shares of Maze Therapeutics worth $836 as of Q2 2026.
  • Cornerstone Financial Management left its Maze Therapeutics share count unchanged in Q2 2026.
  • Maze Therapeutics made up ﹤0.01% of Cornerstone Financial Management's portfolio in Q2 2026, its #1167 holding.
  • Cornerstone Financial Management first reported a position in Maze Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Cornerstone Financial Management's Maze Therapeutics position peaked at $1.16K in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Cornerstone Financial Management's 13F filing for Q2 2026, filed 12 Aug 2026.